Skip NavigationSkip to Content

Development of Genetic Vaccines For Pathogenic Genes - Construction of Attenuated Vif Dna Immunization Cassettes

  1. Author:
    Ayyavoo, V.
    Nagashunmugam, T.
    Boyer, J.
    Mahalingam, S.
    Fernandes, L. S.
    Le, P.
    Lin, J.
    Nguyen, C.
    Chattargoon, M.
    Goedert, J. J.
    Friedman, H.
    Weiner, D. B.
  2. Author Address

    Weiner DB UNIV PENN STELLER CHANCE LABS 502 422 CURIE BLVD PHILADELPHIA, PA 19104 USA UNIV PENN DEPT PATHOL & LAB MED PHILADELPHIA, PA 19104 USA UNIV PENN DEPT MED DIV INFECT DIS PHILADELPHIA, PA 19104 USA NCI LAB VIRAL EPIDEMIOL FREDERICK, MD 21701 USA
    1. Year: 1997
  1. Journal: Aids
    1. 11
    2. 12
    3. Pages: 1433-1444
  2. Type of Article: Article
  1. Abstract:

    Objective: To develop a putative immunization cassette using HIV-1 vif accessory gene derived from HIV-1 clinical specimens as a component of a DNA vaccine for HIV-1. Methods: vii genes were cloned from HIV-l-infected patients and the sequence variation present within the patients was analyzed. Prototypic genetic variants were selected and the ability of these clones to induce humoral and cellular immune responses was studied in animals. The selected protective genetic variants were biologically characterized through transcomplementation assays using primary cells infected with a vii-defective HIV-1 proviral clone. Results: Analysis of vii variants from different patients revealed that vii is highly conserved with the open reading frame remaining intact in vivo. It was shown that attenuated vii clones from HIV-l-infected subjects can effectively induce both humoral and cellular responses against Vif protein in mice. Evaluation of the cellular responses in vitro using human cellular targets infected with a clinical HIV-1 isolate showed that vif clones could induce cellular responses capable of destroying the virus. Conclusions: The vif variants developed in this study exhibited non-productive phenotypes, yet were capable of inducing specific immune responses against HIV-1. These constructs could be used as part of a DNA vaccine strategy for HIV-1. This vaccine adaptation strategy could be used for the development of immunogens for any pathogen resulting in cross-reactive immunity and attenuated gene pathogenesis. [References: 49]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel